Re previous comments and posts on Alemtuzumab:Genzyme May Want $60,000 per annum for Its New M.S. Drug
"Based on its superior efficacy Alemtuzumab should command a premium price. However, the cost will affect its cost-effectiveness and its license in the UK under NICE. Ideally we would like to use Alemtuzumab in early MS; a high cost will prevent this from happening. This is not good news for MS'ers; there is a high level of expectation and this news will dampen hopes."